Aurisco Pharmaceutical Co Ltd
SSE:605116
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (26.1), the stock would be worth ¥22.45 (5% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 27.5 | ¥23.61 |
0%
|
| 3-Year Average | 26.1 | ¥22.45 |
-5%
|
| 5-Year Average | 28.4 | ¥24.4 |
+3%
|
| Industry Average | 23.8 | ¥20.45 |
-13%
|
| Country Average | 20.8 | ¥17.9 |
-24%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
A
|
Aurisco Pharmaceutical Co Ltd
SSE:605116
|
9.6B CNY | 27.5 | 23.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 51.6 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 23.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.2 | 28.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 15.3 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 18.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 10.6 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 17.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 10.6 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Aurisco Pharmaceutical Co Ltd
Glance View
Aurisco Pharmaceutical Co Ltd, a notable player in the world of pharmaceuticals, has carved a distinct niche for itself with its focus on the development and manufacturing of specialized active pharmaceutical ingredients (APIs). Founded in China, the company operates in a sector driven by intricate processes and stringent regulations, where high-quality production is paramount. Aurisco has established itself by continuously investing in research and development, ensuring that its production capabilities remain at the forefront of innovation. Its commitment to excellence is reflected in its comprehensive portfolio, which caters to a wide range of therapeutic areas, addressing global healthcare needs with precision and efficiency. Aurisco's business model revolves around not just the production but also the value-added features of customization and compliance. By engaging in contract manufacturing and developing APIs for major pharmaceutical firms worldwide, Aurisco navigates a landscape that balances intricate scientific processes with the practical demands of global distribution. The company's revenue is bolstered by its ability to meet international standards, allowing it to forge crucial partnerships across continents. Aurisco’s adeptness at managing complex supply chains and its strategic positioning within the pharmaceutical sector enable it to capitalize on growth opportunities, reinforcing its status as a vital cog in the global healthcare machinery.
